Grant of Share Options
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your STX notes
London, UK, 13 February 2025: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that on 12 February 2025 it granted share awards in the form of options over ordinary shares in the capital of the Company ("Ordinary Shares") under Shield Therapeutics' Retention and Performance Share Plan ("RPSP") to the Group's Chief Executive Officer ("CEO") as part of his onboarding.
The following options have been granted to Anders Lundstrom, CEO, who is deemed a PDMR:
| Name | Option Plan | Number of Ordinary Shares under Option | Vesting Date |
|---|---|---|---|
| Anders Lundstrom | RPSP | 5,000,000 | Three years from date of grant, subject to Mr Lundstrom remaining in office as at the date of vesting. |
The proportion of total options awarded to Anders Lundstrom is approximately 0.5% of the total number of AIM securities in issue at this time.
Anders Lundstrom currently holds 10,000 ordinary shares in the Company.
| a) | Name | Anders Lundstrom |
| 2. | Reason for the notification | |
| a) | Position/status | Chief Executive Officer |
| b) | Initial notification/ amendment | Initial Notification |
| 3. | Details of the Issuer | |
| a) | Name | Shield Therapeutics plc |
| b) | LEI code | 213800G74QWY15FC3W71 |
| a) | Description of the financial instrument Identification code | Options over new Ordinary Shares ISIN: GB00BYV81293 |
| b) | Nature of the transaction | Grant of awards over new Ordinary Shares under the Company's Retention and Performance Share Plan. |
| c) | Price(s) and volumes(s) | 2025 RPSP Award Price (£) Volume 0.037 5,000,000 |
| d) | Aggregated information - Aggregate volume - Price | Awards granted over 5,000,000 shares in total 3.7p exercise price |
| e) | Date of the transaction | 12 February 2025 |
| f) | Place of the transaction | Outside of trading venue |
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.